Bank of The West increased its position in CVS Health Corp (NYSE:CVS) by 0.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 57,491 shares of the pharmacy operator’s stock after buying an additional 455 shares during the period. Bank of The West’s holdings in CVS Health Corp were worth $5,621,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Nordea Investment Management AB boosted its stake in CVS Health Corp by 20.5% in the fourth quarter. Nordea Investment Management AB now owns 5,203,605 shares of the pharmacy operator’s stock worth $508,756,000 after buying an additional 886,903 shares during the last quarter. Janus Capital Management boosted its stake in CVS Health Corp by 12.1% in the third quarter. Janus Capital Management now owns 5,971,074 shares of the pharmacy operator’s stock worth $576,089,000 after buying an additional 643,902 shares during the last quarter. Verde Servico Internacionais bought a new stake in CVS Health Corp during the fourth quarter worth $56,485,000. Boston Advisors boosted its stake in CVS Health Corp by 258.7% in the fourth quarter. Boston Advisors now owns 398,639 shares of the pharmacy operator’s stock worth $38,975,000 after buying an additional 287,504 shares during the last quarter. Finally, Windward Capital Management Company boosted its stake in CVS Health Corp by 34.1% in the fourth quarter. Windward Capital Management Company now owns 378,783 shares of the pharmacy operator’s stock worth $37,034,000 after buying an additional 96,373 shares during the last quarter.

Shares of CVS Health Corp (NYSE:CVS) opened at 94.34 on Thursday. CVS Health Corp has a 52-week low of $81.37 and a 52-week high of $113.65. The stock has a market capitalization of $104.72 billion and a price-to-earnings ratio of 21.29. The company has a 50 day moving average of $95.61 and a 200 day moving average of $100.57.

CVS Health Corp (NYSE:CVS) last posted its quarterly earnings results on Friday, October 30th. The pharmacy operator reported $1.28 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.29 by $0.01. During the same quarter in the prior year, the company posted $1.15 earnings per share. The company earned $38.50 billion during the quarter, compared to analyst estimates of $37.81 billion. The company’s quarterly revenue was up 10.3% on a year-over-year basis. Analysts predict that CVS Health Corp will post $5.17 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 2nd. Shareholders of record on Friday, January 22nd will be given a $0.425 dividend. This represents a $1.70 annualized dividend and a yield of 1.80%. This is an increase from CVS Health Corp’s previous quarterly dividend of $0.23. The ex-dividend date of this dividend is Wednesday, January 20th.

A number of analysts have weighed in on CVS shares. Vetr cut shares of CVS Health Corp from a “strong-buy” rating to a “buy” rating and set a $108.12 price objective on the stock. in a report on Monday, November 9th. S&P Equity Research raised shares of CVS Health Corp to a “strong-buy” rating and set a $121.00 price objective on the stock in a report on Tuesday, November 3rd. Barclays started coverage on shares of CVS Health Corp in a report on Friday, December 18th. They set an “overweight” rating and a $110.00 price objective on the stock. Zacks Investment Research cut shares of CVS Health Corp from a “buy” rating to a “hold” rating in a report on Monday, November 2nd. Finally, Citigroup Inc. cut their price objective on shares of CVS Health Corp from $120.00 to $105.00 and set a “neutral” rating on the stock in a report on Thursday, November 12th. Five investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $113.39.

In other CVS Health Corp news, CEO Larry J. Merlo sold 46,393 shares of the stock in a transaction on Monday, January 11th. The stock was sold at an average price of $95.00, for a total value of $4,407,335.00. Following the sale, the chief executive officer now directly owns 161,613 shares of the company’s stock, valued at $15,353,235. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

CVS Health Corporation, together with its subsidiaries, is a pharmacy company. The Company operates through three business segments: Pharmacy Services, Retail Pharmacy and Corporate. The Pharmacy Services segment provides a range of pharmacy benefit management (NYSE:CVS) services and operates under the CVS/caremark Pharmacy Services, Novologix and Navarro Health Services names. The Retail Pharmacy segment sells prescription drugs and an assortment of general merchandise, including over-the-counter drugs, beauty products and cosmetics, personal care products, convenience foods, photo finishing, seasonal merchandise and greeting cards through the Company’s retail stores, online retail pharmacy Websites and retail healthcare clinics. The Corporate segment provides management and administrative services to support the overall operations of the Company. The Company, through its wholly owned subsidiary, Omnicare, Inc., provides pharmacy services to long term care facilities.

12 Month Chart for NYSE:CVS

Receive News & Ratings for CVS Health Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corp and related companies with MarketBeat.com's FREE daily email newsletter.